Bristol-Myers Squibb, CHECKMATE-76K, FDA, melanoma, Opdivo
Nivolumab is approved by the FDA for adjuvant treatment of Stage IIB/C melanoma
Nov 2023: Nivolumab (Opdivo, Bristol-Myers Squibb Company) was granted approval by the Food and Drug Administration as an adjuvant therapy for Stage IIB/C melanoma in patients 12 years of age and older who had undergone complete..